You are here

  • Home
  • Archive
  • Volume 65, Issue Suppl 1
  • PTH-083 Cost-Effectiveness of Vedolizumab Compared with Conventional Therapy for Treatment of Moderately-to-Severely Active Ulcerative Colitis in The United Kingdom

Article info

Article menu
Download PDFPDF
BSG 2016
PTH-083 Cost-Effectiveness of Vedolizumab Compared with Conventional Therapy for Treatment of Moderately-to-Severely Active Ulcerative Colitis in The United Kingdom

Authors

Citation

Wilson M, Kerrigan M, Smyth M, et al
PTH-083 Cost-Effectiveness of Vedolizumab Compared with Conventional Therapy for Treatment of Moderately-to-Severely Active Ulcerative Colitis in The United Kingdom
Gut 2016;65:A260.

Publication history

  • First published August 17, 2016.
Online issue publication 
August 17, 2016

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions